Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;23(6):655-656.
doi: 10.1016/S1473-3099(23)00278-5. Epub 2023 May 3.

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant

Daichi Yamasoba  1 , Keiya Uriu  2 , Arnon Plianchaisuk  3 , Yusuke Kosugi  2 , Lin Pan  4 , Jiri Zahradnik  5 ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Jumpei Ito  6 , Kei Sato  7
Affiliations

Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant

Daichi Yamasoba et al. Lancet Infect Dis. 2023 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

KS reports funding from the Japan Agency for Medical Research and Development (AMED) Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA programme (JP223fa627001); AMED SCARDA Program on R&D of New Generation Vaccine Including New Modality Application (JP223fa727002); AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP22fk0108146, JP21fk0108494, JP21fk0108425, JP21fk0108432, JP22fk0108511, JP22fk0108516, and JP22fk0108506); AMED Research Program on HIV/AIDS (JP22fk0410039); Japan Science and Technology Agency (JST) Core Research for Evolutional Science and Technology (CREST; JPMJCR20H4); Japan Society for the Promotion of Science (JSPS) Core-to-Core Program (Advanced Research Networks; JPJSCCA20190008); and the Cooperative Research Program (Joint Usage/Research Center programme) of the Institute for Life and Medical Sciences at Kyoto University. JI reports funding from JST Precursory Research for Embryonic Science and Technology (PRESTO; JPMJPR22R1) and JSPS KAKENHI Grant-in-Aid for Early-Career Scientists (20K15767and 23K14526). KU reports funding from JSPS Research Fellow DC2 (22J11578). JZ reports funding from Programme EXCELES, a project of the Czechia National Institute of Virology and Bacteriology, funded by the European Union's NextGenerationEU (LX22NPO5103); and the International Joint Usage/Research Center, Institute of Medical Science, The University of Tokyo (K23-3095). The G2P-Japan Consortium also received funding from the AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP21fk0108494 and JP22fk0108511). DY, KU, AP, YK, and LP contributed equally to this study. Members of The Genotype to Phenotype Japan (G2P-Japan) Consortium are listed in the appendix (p 16).

References

    1. WHO Tracking SARS-CoV-2 variants. March 30, 2023. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants
    1. Zahradnik J, Marciano S, Shemesh M, et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat Microbiol. 2021;6:1188–1198. - PubMed
    1. Tamura T, Ito J, Uriu K, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two omicron subvariants. bioRxiv. 2022 doi: 10.1101/2022.12.27.521986. published online Dec 27. (preprint). - DOI - PMC - PubMed
    1. Smith DJ, Lapedes AS, de Jong JC, et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004;305:371–376. - PubMed